Error loading player: No playable sources found

AM24-MN-31-O

AM24-MN-31-O: Cell Therapy: Creative Inventory Management & Discard (Enduring)

Date
October 23, 2024
Credits
1.5 General Continuing Education (GEN) | 1.5 Florida Lab Personnel (FLP) | 1.5 California Nurse (CN) | 1.5 California Lab Personnel (CLP) | 1.5 Physician (PHY)
$30
Standard Price
Members save $5
This product is also available as part of the following products:
Thumbnail for 2024 AABB Annual Meeting On-Demand: BIOTHERAPIES SESSIONS
Interested in all sessions Cellular Therapy/Biotherapies? Then this is the package for you. We have also thrown in a couple of additional sessions you might also find interesting…
Thumbnail for 2024 AABB Annual Meeting On-Demand: CABP CE Eligible Sessions
Interested in sessions eligible to maintain your AABB Certified Advanced Biotherapies Professional (CABP) certification? This package provides:
Thumbnail for 2024 Annual Meeting On-Demand: FULL ACCESS
By far the best value to watch all the on-demand educational sessions from the 2024 AABB Annual Meeting and earn continuing education credit…

CABP CE Eligible

A presentation of how one facility tackled a massive inventory reduction project to discard cell therapy products that had been in LN2 storage for 10 to 25 years. The project involved the hospital legal department, medical director, transplant physicians, Lab Director, Quality and Regulatory Manager, Lab Supervisor and staff, the hospital Mail Department and the Cell Therapy Storage Agreement signed by the donor and recipient. Hundreds of products that had been in long term storage were discarded with patient and physician notification and permission, and two large LN2 freezers were completely emptied. We will share some of the questions that patients asked about discard of their products during the project. We will demonstrate our electronic database, internally developed by our hospital. This database is used to track cell therapy products once collected and cryopreserved, placed in storage, and then later removed for infusion, distribution and/or discard. We will describe the cell therapy product rack numbering system. The inventory management system easily identifies if a cell therapy product is designated for transplant, boost, or backup, just by the rack numbering rank and location. This project eliminated the prior system of inventory management documented on paper. The presentation will include a description of the electronic and paper downtime methods. Two to three speakers will address administrative tasks of developing algorithms for products to evaluate for discard, how we involved the hospital legal department to protect the hospital from liability, creation of discard consent forms, obtaining IT support, hands-on steps involved to label and number canisters and racks, mail certified letters, discard cell therapy products. Lecture will describe how we created and validated the electronic inventory management database; and how we verified the location of each product in electronic and physical inventory. We will describe the audit program we have developed for verifying the inventory management system works. We will emphasize that each facility will need to consult their own legal team and we will present how our hospital accomplished this task and include a list of legal topics for facilities to consider, including addressing whether there are family rights to cell therapy products if a patient dies.

Learning Objectives

  • Apply the regulations and standards regarding storage, distribution and discard of cell therapy products.
  • Illustrate the method of obtaining approval to discard cell therapy products. Demonstrate and describe the discard process from start to finish.
  • Demonstrate how an electronic database was created and used to replace paper inventory management.
  • Reorganize and renumber LN2 storage racks by bag size and volume.
  • Organize product storage racks to keep same size products in one area and reduce the number of older, less efficient LN2 freezers through product discard so new LN2 freezers can be purchased.

Moderator

Speaker Image for Brenda Alder
Brenda Alder, MS, MLS(ASCP)SBB, CABPH(AABB)
Northside Hospital Atlanta

Speakers

Speaker Image for Jennifer Westerman
Northside Hospital Atlanta
Speaker Image for Rupal Brahmbhatt
Rupal Brahmbhatt, MLS (AMT), CABP (AABB)
Northside Hospital Atlanta

Related Products

Thumbnail for AM24-TU-06-O: Oral Abstracts - Biotherapy Spotlight (Enduring)
AM24-TU-06-O: Oral Abstracts - Biotherapy Spotlight (Enduring)
The Biotherapies Spotlight Session will cover several diverse topics. The use of controlled incremental filtration microfluidics rather than monoclonal antibody selection systems to isolate B-cells from whole blood will be discussed…
Thumbnail for AM24-MN-32-O: Lyophilized, Stem-cell Derived, and Synthetic Platelet Products are Closer Than You May Think (Enduring)
AM24-MN-32-O: Lyophilized, Stem-cell Derived, and Synthetic Platelet Products are Closer Than You May Think (Enduring)
This session will highlight advances in three areas of platelet research; stabilization methods through lyophilization, iPSC ex-vivo production, and synthetic nanoparticle technology are converging and can lead to long-lived platelet-based therapies targeted to address specific related pathologies…
Thumbnail for AM24-MN-34-O: Mechanisms and Technologies Towards Expanding Hematopoietic Stem Cells for Transplantation (Enduring)
AM24-MN-34-O: Mechanisms and Technologies Towards Expanding Hematopoietic Stem Cells for Transplantation (Enduring)
Hematopoietic stem cells (HSCs) are the apex hematopoietic cell with the potential to produce robust and lifelong production of all blood cells. Thus, understanding the details of HSC molecular biology is critical to our understanding of human health and longevity…
Thumbnail for AM24-TU-10-O: Is Your Firm Ready for an FDA Office of Inspections and Investigations Inspection?  Hear about the Most Frequently Cited Observations and Inspectional Process from FDA’s Office of Biologics Inspectorate (Enduring)
AM24-TU-10-O: Is Your Firm Ready for an FDA Office of Inspections and Investigations Inspection? Hear about the Most Frequently Cited Observations and Inspectional Process from FDA’s Office of Biologics Inspectorate (Enduring)
This informative session will give an overview of inspections conducted by FDA’s Office of Inspections and Investigations (OII), Office of Biologics Inspectorate (OBI), including OBI’s role in regulatory inspections and current regulatory oversight…